Evidence map›Paper›PMID 29125481›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.

Chunlei Cong, Wenbo Wang, Jun Tian, Tianqi Gao, Weizhuo Zheng, Changlin Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Liquid biopsies in primary and secondary bone cancers.Cancer drug resistance (Alhambra, Calif.) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chunlei CongDepartment of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Wenbo WangDepartment of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jun TianDepartment of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Tianqi GaoDepartment of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Weizhuo ZhengDepartment of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Changlin ZhouDepartment of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Second Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt has been demonstrated that microRNAs (miRNAs) play an important role in the carcinogenesis of osteosarcoma.

objectiveThe aim of the present study was to determine the diagnostic and prognostic value of serum miR-124 in osteosarcoma.

methodsThe serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR).

resultsThe level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p< 0.05). The serum miR-124 levels in osteosarcoma patients were significantly elevated after receiving surgical treatment (p< 0.01). Furthermore, the area under the receiver-operating characteristic (ROC) curve (AUC) for serum miR-124 was 0.846, combining with 79.8% sensitivity and 86.00% specificity. A significant correlation was detected between serum miR-124 expression and distant metastasis (p= 0.0256) as well as clinical stage (p= 0.0006). Similarly, serum miR-124 levels in patients with advanced clinical stage or positive distant metastasis were significantly decreased. Moreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates. Finally, multivariate analysis revealed that serum miR-124 was an independent prognostic indicator for osteosarcoma.

conclusionsThese findings suggested that serum miR-124 might be a promising biomarker with diagnostic and prognostic value for osteosarcoma.

Indexed as

AdolescentAdultBiomarkers, TumorBone NeoplasmsFemaleHumansMaleMicroRNAsOsteosarcomaPrognosisSurvival AnalysisYoung AdultBiomarkers, TumorMicroRNAsMIRN124 microRNA, humandiagnosisosteosarcomaprognosisSerum miR-124

Identifiers

PMID29125481
PMCPMC13078265
OpenAlexW2767981804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.